[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bone-cancer-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bone-cancer-metastatic":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,38,97],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":37},"100582168","a-multi-center-observational-trial-of-symptomatic-high-risk-bone-metastases-treated-with-percutaneous-ablation-and-palliative-radiation-therapy-100582168",false,"NCT06859801","A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy","TRIBUTE","Inclusion Criteria:\n\n* 1\\. Skeletal metastasis with localized pain not controlled medically \\[recall within last 24 hours of worst pain ≥ 5 using the BPI\\]\n* 2\\. Pain must be from one painful metastatic lesion involving the bone (additional less painful metastatic sites may be present). Extra-osseous extension of disease is allowed (must have some contact with the bone and be causing bone\u002Ftumor interface pain)\n* 3\\. Lesions that are at high-risk of skeletal related events defined as follows:\n* a. Minimum Spinal Instability Neoplastic Score (SINS) score ≥ 7 for lesions involving the spine\n* b. Pelvic and appendicular lytic lesions with or without cortical breakthrough causing functional\u002Fmechanical pain\n* 4\\. Target lesion amenable to percutaneous ablation with image guidance AND RT by specialists' review\n* 5\\. No prior targeted radiation therapy or ablation to the index lesion\n* 6\\. ECOG performance status 0-2\n* 7\\. Age ≥ 21 years\n* 8\\. Have signed the current approved informed consent form\n* 9\\. Willing and able to answer follow-up Patient Reported Outcomes (PRO) surveys (e.g., PROMIS®, BPI, COST-FACIT, and OMED) for up to 12 months\n* 10\\. Life expectancy \\> 3 months\n\nExclusion Criteria:\n\n* 1\\. Any medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial.\n* 2\\. Target tumor involves a weight-bearing long bone of the lower extremity with the tumor causing \\> 50% loss of cortical bone \\[MIREL Score ≥ 7\\]\n* 3\\. Skeletal lesions with unstable pathologic fractures requiring immediate surgical stabilization\n* 4\\. Concurrent participation in other studies that could affect the primary endpoint\n* 5\\. Target tumor causing clinical or imaging evidence of spinal cord compression","ALL","21 Years",{"count":19,"type":20},120,"ESTIMATED","OBSERVATIONAL","The objective of this study is to evaluate real-world outcomes (e.g., pain, patient reported outcomes, skeletal related events, healthcare utilization, etc.) in patients treated with both percutaneous ablation and palliative radiation therapy (RT).",[24],"Bone Cancer Metastatic","RECRUITING","2026-06-04",{"date":28,"type":29},"2026-06-05","ACTUAL",{"date":31,"type":29},"2025-10-23",{"date":33,"type":20},"2027-07-31",{"name":35,"class":36},"Society of Interventional Oncology","OTHER",7,{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":64,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":5},"100642988","registry-of-minimally-invasive-cancer-treatment-using-spectral-angio-ct-image-guidance-100642988","NCT07636148","Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance","Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice","PreciseOnco","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;\n* Use of spectral angio-CT image guidance as part of standard care;\n* Written confirmed consent.\n\nExclusion Criteria:\n\n* Patients who are declared incapacitated;\n* Patients suffering from psychic disorders that make a comprehensive judgement impossible.","18 Years",{"count":48,"type":20},2000,"3 Years","This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone.\n\nDuring these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results.\n\nNo experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.",[52,53,24,54,55,56,57,58,59,60,61,62,63],"Liver Cancer (Primary and Metastatic)","Lung Cancer (Diagnosis)","Bone Cancer Tumor","Kidney Tumors","Renal Cancer","Hepatocellular Carcinoma (HCC)","Renal Cell Carcinoma (Kidney Cancer)","Renal Cell Carcinoma (RCC)","Musculoskeletal Cancers","Musculoskeletal Tumors","Bone Tumors","Lung Tumors",[65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86],"Spectral CT","Dual-layer detector CT","Angio-CT","Image-guided therapy","Interventional oncology","Thermal ablation","Radiofrequency ablation","Microwave ablation","Cryoablation","Transarterial chemoembolization","Transarterial radioembolization","Transarterial embolization","Local tumor control","Tumor recurrence","Progression-free survival","Hepatocellular carcinoma","Liver metastases","Renal cell carcinoma","Lung tumors","Musculoskeletal tumors","Registry","Multicenter","NOT_YET_RECRUITING","2026-06-03",{"date":90,"type":29},"2026-06-09",{"date":92,"type":20},"2026-07-01",{"date":94,"type":20},"2030-12-31",{"name":96,"class":36},"Mark C Burgmans, MD PhD",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":122},"100571134","effectiveness-of-radiofrequency-ablation-and-stabilization-in-metastatic-spine-lesions-by-positron-emission-computed-tomography-pet-ct-confirmation-100571134","NCT06716294","Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By Positron Emission Computed Tomography (PET-CT) Confirmation","Effectiveness Of Radiofrequency Ablation And Stabilization In Metastatic Spine Lesions By PET-CT Confirmation","ABLASPINE","Inclusion Criteria:\n\n* only patients with secondary osteolytic and mixed (lytic and sclerotic) spine tumors with one to three active lesions will be enrolled.\n* lesions to be treated must be metabolically active on PET-CT performed during the last month.\n* Patients will be informed and sould sign an inform consent.\n* post treatment patients should submittes a new PET-CT in order to verify the activity of the treated area.\n\nExclusion Criteria:\n\n\\-","90 Years",{"count":107,"type":20},16,"This pilot study will try to demonstrate metabolic changes in spine lesions treated by Augmentation and Ablation, according to existing standards of practice. Our purpose is to show the efficacy of a new radiofrequency ablation (RFA) in combination with augmentation, using a percutaneous ablation device (Osteocool-Medtronic) in the treatment of secondary vertebral bone tumor, avoiding concurrent bias related to other treatments of the disease.",[24,110,111,112],"Radiofrequency Ablation","Spine Metastases","Vertebral Metastasis","2026-04-06",{"date":115,"type":29},"2026-04-09",{"date":117,"type":29},"2023-01-01",{"date":119,"type":20},"2028-12-31",{"name":121,"class":36},"National and Kapodistrian University of Athens",1]